Pfizer on Wednesday said its experimental vaccine targeting the potentially deadly bacterial disease Group B Streptococcus returned strong mid-stage clinical trial results, a promising step as the drug inches toward potential approval.
Pfizer is among several drugmakers racing to develop the world's first shot targeting Group B strep disease, which is linked to nearly 150,000 infant deaths worldwide each year, especially in lower-income countries.
Pfizer's single-dose shot generated antibodies that may provide infants with meaningful protection against the disease, according to the data released Wednesday from a phase two clinical trial.
Pfizer's encouraging phase two trial results provide hope that maternal vaccination against the disease, also known as GBS, could help prevent thousands of cases in babies.
The results will also help the company plan its phase three clinical trials on the shot, which are typically required before the FDA approves a drug.
Persons:
Streptococcus, Melinda Gates
Organizations:
Pfizer, Drug Administration, FDA, Melinda Gates Foundation